key: cord-0755492-orw69y3q authors: Esposito, Giuseppe; Pesce, Marcella; Seguella, Luisa; Sanseverino, Walter; Lu, Jie; Corpetti, Chiara; Sarnelli, Giovanni title: The potential of cannabidiol in the COVID‐19 pandemic: a hypothesis letter date: 2020-06-10 journal: Br J Pharmacol DOI: 10.1111/bph.15157 sha: c979409a13a71de6115f7300e72b0c34ebcafd0b doc_id: 755492 cord_uid: orw69y3q Identifying candidate drugs effective in the new coronavirus disease 2019 (Covid‐19) is crucial, pending a vaccine against SARS‐CoV2. We suggest the hypothesis that Cannabidiol (CBD), a non‐psychotropic phytocannabinoid, has the potential to limit the severity and progression of the disease for several reasons: 1) High‐CBD Cannabis Sativa extracts are able to downregulate the expression of the two key receptors for SARS‐CoV2 in several models of human epithelia 2) CBD exerts a wide range of immunomodulatory and anti‐inflammatory effects and it can mitigate the uncontrolled cytokine production featuring Acute Lung Injury 3) Being a PPARγ agonist, it can display a direct antiviral activity 4) PPARγ agonists are regulators of fibroblast/myofibroblast activation and can inhibit the development of pulmonary fibrosis, thus ameliorating lung function in recovered patients. We hope our hypothesis, corroborated by several preclinical evidence, will inspire further targeted studies to test CBD as a support drug against the COVID‐19 pandemic. Respiratory syncytial virus (RSV), Hepatitis B virus (HBV), Hepatitis C Virus (HCV), Cytochromes P450 (CYP450), half inhibitory concentration (IC50). Dear editor, An aberrant release of cytokines and proinflammatory molecules is closely related to lung injury, multiorgan failure and ultimately poor prognosis in the new Severe Acute Respiratory Syndrome -Coronavirus -2 (SARS-CoV2) pandemic [Huang et al. 2020 ]. Such uncontrolled release of cytokines, namely interleukin (IL)-1ß, IL-6, monocyte chemoattractant protein (MCP)-1, paralleled with the decreased natural killer cells may result in the so-called 'cytokine storm'. Immune dysregulation, rather than viremia levels per se, has been related to the massive proinflammatory cytokine secretion by alveolar macrophages, and subsequent CD4 + and CD8 + T cell dysfunction observed in SARS-CoV infection [Channappanavar et al. 2016 ]. Hence, until specific vaccines become available, the use of antiviral agents alone may not be sufficient to stop the cytokine storm and respiratory distress in severely-ill patients. In the attempt of reducing their overall mortality, it is therefore essential to identify new therapeutics able of mitigating the cytokine storm [Huang et al. 2020 ]. Nonetheless, redundancies within the complex cytokine network still represent a major obstacle to monoclonal antibodies therapies. The ideal drug candidate should be already in use for other indications, have a favorable safety profile and a multitargeted action, able to synergistically mitigate the cytokine storm, acting as an immunomodulatory rather than an immunosuppressant drug. In a recent paper, high-cannabidiol (CBD) Cannabis Sativa extracts have been reported to downregulate Angiotensin-converting enzyme 2 (ACE2) and Transmembrane Serine Protease 2 (TMPRSS2) receptors, crucial viral gateways in oral, lung and intestinal epithelia constituting important routes of SARS-CoV2 invasion [Wang et al 2020] . By downregulating ACE2 and TMPRSS2 receptors, the authors suggested high-CBD products, such as mouth washes, as a preventative strategy in COVID-19 infection to limit SARS-CoV2 entry into susceptible hosts. While this article puts forward the concept that cannabinoids-containing products may serve as a preventative treatment for topical use, there is evidence suggesting that CBD immunomodulatory activities may play a role in later stages of the disease. We herein explore the hypothesis that systemic administration of CBD could have the potential to limit COVID-19 disease progression and post-infectious sequelae. Non-psychotropic phytocannabinoid CBD is considered one of the most interesting emerging molecules in the field of pharmacology, since it exerts a wide range of therapeutic effects, ranging from anticonvulsive, sedative, hypnotic, antipsychotic, anti-cancer, antiinflammatory and neuroprotective activities [Iffland and Grotenhermen, 2017] . Lacking of the unwanted psychotropic effects of marijuana derivatives, CBD has little binding affinity to cannabinoid receptors (acting as allosteric modulator of cannabinoid CB1 receptors) and a favorable safety profile in humans [Iffland and Grotenhermen, 2017] . CBD acts as a powerful antioxidant acting at various receptor sites, including peroxisome proliferator-activated receptor gamma (PPAR), 5-hydroxytryptamine (5HT)-1A, Adenosine A2, transient receptor potential (TRP) channels receptors to directly or indirectly display a wide range of antiinflammatory and immunomodulatory effects. A complete review of CBD receptor targets is beyond the purpose of the present article and the readers are invited refer to more extensive review on this subject [Iffland and Grotenhermen, 2017] . Such pleiotropic pharmacological activity has been tested in various pathological conditions, including respiratory diseases resembling COVID19-induced respiratory distress. Acute Lung injury (ALI) refers to a characteristic form of parenchymal lung disease, featured by bilateral pulmonary infiltrates, alveolar-capillary vasculitis with neutrophil infiltration and proinflammatory cytokines release, comparable to COVID19. By acting at adenosine A2 receptor site, CBD caused a marked amelioration of the pulmonary function [Ribeiro et al. 2015 , Ribeiro et al. 2012 ] as a consequence of the significantly decreased lung resistance and elastance due to the reduction of leukocyte migration into the lung, accompanied to a marked inhibition of both pro-inflammatory cytokines (TNF and IL-6) and chemokines (MCP-1 and MIP-2) released [Ribeiro et al. 2015 , Ribeiro et al. 2012 . Although limited to interesting preclinical studies, scattered evidence also points towards a possible use of CBD in viral infections. Indeed, several plant-derived compounds have evolved to display antiviral activity, including many phenol-based compounds, such as terpenoids. CBD and other cannabinoids exert their activity through the interaction with the nuclear peroxisome proliferator-activated receptors (PPARs) [O'Sullivan and Kendall, 2010] . The PPARs belong to the family of nuclear hormone receptors and their activity is regulated by steroids and lipid metabolites. Three different PPAR isoforms (PPARα, PPARβ, also called δ, and PPAR) have been identified and they have been described to regulate the expression of genes related to lipid and glucose homeostasis and inflammatory responses. PPAR agonism in resident alveolar macrophages significantly limits pulmonary inflammation and promotes host recovery following respiratory viral infections [Huang et al., 2019] . As it has been demonstrated during acute pneumonia, alveolar macrophage largely express PPAR. PPAR activation is also responsible for the control of cytokine oversecretion with consequent amelioration of the tissue damage. It is therefore likely that in addition to directly determining an improvement in lung dynamics, CBD could significantly counteract the onset of the cytokine storm from resident macrophages. Interestingly, prophylactic or therapeutic administration of PPAR agonists led to reduction of morbidity and mortality during influenza A virus infection [Bassaganya-Riera et al. 2010] . Not coincidentally, the opportunity of thiazolidinediones repurposing for the treatment of COVID-19 patients has been recently suggested, based on their activity on PPAR receptors [Carboni et al. 2020 ]. Nonetheless, full PPARγ agonists bear several unwanted side effects that could limit their clinical applicability in COVID-19 infection. The use of thiazolidinediones indeed suffered a back-box warning from the FDA given the risk of cardiovascular complications, such as acute myocardial infarction, heart failure and stroke. Conversely, being a weak PPARγ agonist, CBD may overcome these limitations and be voided of these side effects [Graham et al. 2010 ]. Hepatitis C Virus. Noteworthy, these experimental evidences are corroborated by recent study showing a direct antiviral against HCV in vitro [Lowe et al. 2017 ]. Recent reports show that a subset of COVID-19 survivors can develop post-infectious sequelae with persistently impaired lung function and pulmonary fibrosis [Ng et al. 2020 ]. PPAR-γ receptors represent a potential therapeutic target in fibrotic lung diseases, given their ability of regulating fibroblast/myofibroblast activation and collagen secretion in murine models [Milam et al. 2008] . Notably, CBD has been shown to reduce pulmonary inflammation and fibrosis in animal models of asthma [Vuolo et al. 2018] . It is therefore conceivable to speculate that, being a PPAR-γ receptor agonist, CBD can potentially limit the onset of late-onset pulmonary fibrosis in COVID19-recovered patients. Although CBD is a relatively safe molecule for humans and different trials have been conducted [Millar et al. 2019] or are ongoing, especially in the field of neurological disorders therapy; there are currently no evidences about the efficacy and relative toxicity of CBD in COVID19. Even if CBD was (incorrectly in our opinion) considered as a mere therapeutic supplement, there is still lack of data regarding the relative toxicity profile in co-administration with other drugs in the current anti-COVID19 protocols. According to a precautionary principle, a possible strategy would be testing CBD therapeutic potential in COVID-19 patients (aged 18 years or older) either at an early stage of the disease to stop the cytokine storm and development of respiratory distress, or alternatively, to evaluate its effectiveness in COVID-19 recovered patients to prevent pulmonary fibrosis. CBD effects in vivo largely depend on its doses and the bioavailability of its receptor targets in various pathological conditions. Different plasmatic concentrations of CBD may be required in order to activate the distinct pathways responsible for its multifaceted activity; indeed, subtherapeutic dosing (0.3 mg/kg/die) has been suggested to account for CBD lack of effectiveness in Crohn's disease [Millar et al. 2019] . In humans, CBD has been tested across a wide dosage range, varying from <1 up to 50 mg pro kg/die depending on the trials and on the explored pathological condition, with both in vitro and in vivo studies suggesting an immunosuppressive action at higher concentrations or doses. Both in HIV and in post-Ebola syndrome, CBD has been proposed as a therapeutic agent to control immune activation at the doses of 10-20 mg/kg/die and 1.7-10 mg/kg/d (100 mg/die titrating up to 600 mg/die), respectively [Costiniuk et al, 2019; Reznik et al. 2016] . We suggest that CBD should be given orally starting at 100 mg/day titrating up to 300 mg/day (2.5 mg/kg/die), since this dosage did not produce relevant adverse effects even for prolonged administrations (up to 18 weeks) in clinical trials in humans. However, it is worth mentioning that most of the published clinical trials lack of the effective plasmatic concentrations reached by orally-administered CBD in vivo. This has also implications for its safety profile, since CBD acts as an in vitro inhibitor of several CYP450 isoforms [Millar et al. 2019] . As previously underlined, drug-drug interaction studies between CBD and anti-COVID-19 treatments are lacking; therefore, monitoring of patients for potential drug interactions would be required. Similarly, CYP inhibitors are predicted to increase CBD plasma concentrations and patients should be carefully monitored for adverse effects. Nonetheless, we do not anticipate serious adverse side effects, since the proposed dose of CBD is generally well tolerated in humans and the half inhibitory concentration (IC50) required to inhibit the CYP450 is significantly higher to the plasmatic concentration of CBD achieved following oral administration. Finally, regarding the possible concerns about immunosuppression during acute infections, we believe it is important to underline that CBD did not determine an increased mortality in acutely infected animals; rather, in pneumococcal meningitis, animal survival was increased and TNFα concentrations decreased at the doses of 2.5, 5 and 10 mg/kg [Barichello et al. 2012 ]. The COVID19 pandemic is testing the planet. The off-label use of readily available therapeutics able to limit the severity of the disease must be scrupulously scrutinized, pending a vaccine against SARS-CoV2. In keeping with this, we consider CBD a promise candidate drug to bet on, based on the encouraging preclinical studies and its relative safety profile in humans (figure 1). Further evidence will be needed to confirm its beneficial activities and turn CBD into a useful addition to the treatment of COVID-19. Cannabidiol reduces host immune response and prevents cognitive impairments in Wistar rats submitted to pneumococcal meningitis PPAR-gamma activation as an antiinflammatory therapy for respiratory virus infections Can pioglitazone be potentially useful therapeutically in treating patients with covid-19? Med Hypotheses Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice Oral cannabinoids in people living with HIV on effective antiretroviral therapy: CTN PT028-study protocol for a pilot randomised trial to assess safety, tolerability and effect on immune activation Risk of acute myocardial infarction, stroke,heart failure,and death in elderly Medicare patients treated with rosiglitazone or pioglitazone Macrophage PPAR-γ suppresses long-term lung fibrotic sequelae following acute influenza infection Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies Potential of Cannabidiol for the Treatment of Viral Hepatitis. Pharmacognosy Res PPAR-γ agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis A systematic review of cannabidiol dosing in clinical populations Temporal changes in computed tomography of COVID-19 pneumonia with perilobular fibrosis Cannabinoid activation of peroxisome proliferator-activated receptors: Potential for modulation of inflammatory disease Cannabidiol improves lung function and inflammation in mice submitted to LPSinduced acute lung injury Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury Cannabidiol: a potential treatment for post Ebola syndrome? Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma Search of Preventative Strategies: Novel AntiInflammatory High-CBD Cannabis Sativa Extracts Modulate ACE2 Expression in COVID-19 Gateway Tissues